iCAD Releases Enhanced ProFound Detection Workstation Features to Streamline Mammogram Interpretation for Radiologists
- None.
- None.
Insights
The advancements announced by iCAD in their ProFound Detection system represent a significant step in the field of medical imaging and diagnostic efficiency. By introducing a limit to the number of lesion marks and implementing a color-coding system, the company aims to streamline the workflow for radiologists. This could potentially reduce the time taken to interpret mammograms and prioritize patient cases, which is particularly valuable given the high volume of imaging studies radiologists must review.
From a technology adoption standpoint, the ability to fine-tune the system based on real-world data is a testament to the flexibility and customization that modern medical software must offer to meet diverse clinical needs. This personalization can improve diagnostic accuracy and is indicative of a trend towards more adaptive AI solutions in healthcare.
For stakeholders, these enhancements could translate to improved market competitiveness for iCAD, potentially impacting their stock positively. Increased efficiency in cancer detection not only benefits patient outcomes but also can lead to cost savings for healthcare providers, thus making iCAD's solutions more attractive from a business perspective.
With the introduction of ProFound Detection's latest features, iCAD addresses key challenges in mammography interpretation. The focus on interpretability and efficiency aligns with the healthcare industry's push towards precision medicine and improved patient care. The color-coded ProFound Scorecard is a strategic addition that could enhance decision-making processes for radiologists, potentially reducing diagnostic errors and improving patient triage.
Considering the competitive landscape, iCAD's continuous innovation cycle, as highlighted by the historical progression of their product, keeps the company relevant and ahead in a market where technological advancements are critical for maintaining a leadership position. The emphasis on user customization also suggests that iCAD is responsive to the evolving needs of healthcare practitioners, which may contribute to customer retention and attract new users searching for tailored solutions.
Long-term implications for iCAD may include solidifying their presence in the AI diagnostics space, which is becoming increasingly crowded. By consistently delivering improvements, iCAD may secure long-term contracts with healthcare institutions, thus ensuring a steady revenue stream and potentially boosting investor confidence.
Newly released capabilities -- limiting the number of marks on a 3D view, color-coding lesion marks, and color-coding the ProFound Scorecard -- enhance radiologists' interpretability and efficiency
NASHUA, N.H., March 19, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced new, advanced workstation features for ProFound Detection for both 2D and 3D mammography in its latest V3 Service Pack update.
“We're excited to introduce advanced workstation features for our flagship solution, ProFound Detection, aimed at further improving and facilitating radiologists' interpretation of mammograms within their workstation,” said Dana Brown, President and CEO of iCAD. “With these new capabilities, such as limiting lesion marks to the three highest-scoring lesions, which can be color-coded based on lesion score, and providing color-coded ProFound Scorecards based on case score categories, along with options for fine-tuning based on a facility’s real-world data, we're enhancing radiologists' interpretability and efficiency in cancer detection.”
The new features for the ProFound Detection solution are designed to improve the readability of iCAD results through a configuration option to limit to three lesion marks visible on a workstation view displaying 3D images. This refinement ensures that radiologists can interpret the most critical information thereby streamlining the diagnostic process for more efficient decision-making.
The introduction of color-coded lesion marks and case scores on the ProFound Scorecard provides an intuitive visual aid, allowing radiologists to discern the suspicion level of detected abnormalities quickly. This color-coded system, based on cancer occurrence per screening population, offers a concise, comprehensive representation of the severity of detected lesions and the overall case, further aiding in accurate diagnoses and prioritization of cases.
Support for fine-tuning score ranges based on a facility’s own real-world data enables users to customize the detection system according to their specific clinical needs, enhancing performance and adaptability to varying patient populations.
“The progression of iCAD’s leading Breast Health AI for over 20 years represents our continuous improvement in technology and functionality, demonstrating our unwavering commitment to advancing cancer detection capabilities and improving patient outcomes,” continued Brown. “From the inception of iCAD’s 2D Detection in 2002, to the launch of 3D Detection V1.0 in 2016, followed by 3D V2.0 Detection in 2018, and V3.0 Detection in 2021, each version has pushed the boundaries of cancer detection solutions. Now, in 2024, the release of the V3 Detection Service Pack marks another milestone, representing a commitment to ongoing enhancement and ensuring that ProFound Detection remains at the forefront of early cancer detection solutions.”
About iCAD, Inc.
iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly
Forward-Looking Statements
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening in light of risks of potential exposure to Covid-19, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
CONTACTS
Media inquiries: pr@icadmed.com
Investor Inquiries: ir@icadmed.com
FAQ
What are the new advanced features introduced by iCAD, Inc. for its ProFound Detection solution?
How do the new features aim to enhance radiologists' interpretability and efficiency?
What is the significance of limiting lesion marks in the new features?
How do color-coded lesion marks and ProFound Scorecards benefit radiologists?
How does the support for fine-tuning score ranges enhance the detection system?
